Rapid Fire 8
Session Details
Moderator
Hope S Rugo, City of Hope Comprehensive Cancer Center, Duarte, CA
Presentation numberRF8-1
Excellent Long Term Outcomes Irrespective of Chemotherapy Use or Age for Clinically High and Genomically UltraLow Risk Early Breast Cancer in the MINDACT trial
Laura van t Veer, University California San Francisco, San Francisco, CA
Presentation numberRF8-2
2b or not 2b: updated results from the wisdom 1.0 study show continued reduction in locally advanced cancers in the risk-based arm
Laura Esserman, University of California, San Francisco, San Francisco, CA
Presentation numberRF8-3
Loco-regional irradiation in patients with clinical N1 biopsy-proven axillary node involvement at presentation who become pathologically node-negative after neoadjuvant chemotherapy: 8-year outcome results of NRG Oncology/NSABP B-51/RTOG 1304
Eleftherios P Mamounas, AdventHealth Cancer Institute, Orlando, FL
Presentation numberRF8-4
A phase II trial of datopotamab deruxtecan (Dato-DXd) or trastuzumab deruxtecan (T-DXd) in patients with HER2-negative (HER2-low or HER2-0) metastatic breast cancer (mBC) after progression on prior antibody drug conjugate therapy: Primary results from Arm E (Dato-DXd after T-DXd for HR-positive/HER2-negative mBC) of the TRADE-DXd trial (TBCRC 064)
Ana C Garrido-Castro, Dana-Farber Cancer Institute, Boston, MA
Presentation numberRF8-5
Treatment discontinuations and patient-reported outcomes in lidERA Breast Cancer: A Phase III trial of giredestrant in patients with estrogen receptor-positive, HER2-negative early breast cancer
Sara A Hurvitz, Fred Hutchinson Cancer Center, Seattle, WA
Presentation numberRF8-6
Adjuvant giredestrant in combination with abemaciclib in high-risk, estrogen receptor-positive, HER2-negative early breast cancer: Initial results from a substudy of the Phase III lidERA Breast Cancer trial
Rena D. Callahan, UCLA David Geffen School of Medicine, Los Angeles, CA